ASH 2024: Updates in the Treatment of CLL - Episode 8
Expert Insights: Treatment Selection in Second-Line R/R CLL and Limitations of Applying MAIC Data in the Real-World Practice Setting
Panelists discuss how second-line treatment selection in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) requires careful consideration of prior therapy exposure, with noncovalent Bruton tyrosine kinase (BTK) inhibitors showing particular promise for patients with BTK resistance mutations while noting that matching-adjusted indirect comparisons (MAIC) analyses, though informative, must be interpreted cautiously in the absence of direct comparative trials.
Video content above is prompted by the following:
- Switching gears to the R/R CLL population, what is your general treatment approach in the second-line setting?
- How does prior first-line therapy influence your treatment decision?
- In what clinical scenarios may you consider a noncovalent BTK inhibitor for patients with R/R CLL?
- There have been multiple MAIC analyses reported out so far. What are your thoughts, and how do you interpret this data and apply it to real-life day to day practice without head-to-head randomized controlled trials?
Related Content:
